NASDAQ

Nasdaq_Closing_BiondVax

About this Marketsite Event

BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a pharmaceutical company dedicated to the development of a Universal Flu Vaccine, covering all human strains and providing protection for both seasonal and pandemic flu strains, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Dr. Ron Babecoff, Chief Executive Officer rang the Closing Bell.

BiondVax Pharmaceuticals, a publicly-traded company (TASE:BNDX) (Nasdaq:BVXV) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax’s Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company’s Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone, a blockbuster drug for the treatment of multiple sclerosis.

Media from the Event

Photos and videos have been posted on BiondVax’s website: photos | videos.

Read more on Nasdaq’s website: http://www.nasdaq.com/marketsite/marketsite-events-detail.aspx?fn=201507-close07102015.txt#3#ixzz3flXTN6BE